Glaucoma is the leading cause of irreversible blindness in the world, with a prevalence of approximately 3.5% of people between the ages of 40 and 80 years, worldwide.
1 Glaucoma is an intraocular pressure (IOP)-dependent disease, and the only established treatment is to lower the IOP.
2 Topical medication, laser therapy, and surgery have been performed to lower IOP, depending on the patient's condition.
3 Trabeculectomy is the gold standard, the most widely used approach in glaucoma surgery,
4 and its IOP-lowering effect is well-established.
5,6 Ex-PRESS (Alcon, Fort Worth, TX) minishunt surgeries have been performed worldwide.
7 The principle of IOP reduction is the same as that in trabeculectomy. However, in Ex-PRESS shunt surgery, instead of resection of the scleral block and peripheral iridectomy, a short implant made of stainless steel is inserted under the scleral valve into the anterior chamber.
8 Because Ex-PRESS insertion stabilizes aqueous humor outflow compared with traditional trabeculectomy, the reported frequency of postoperative hypotony is lower with Ex-PRESS shunts than with trabeculectomy.
9 Additionally, there is no need for procedures such as iridectomy and scleral block resection with Ex-PRESS implantation, which has been shown to avoid intraoperative bleeding and potentially decrease postoperative inflammation.
10 Indeed, some meta-analyses based on clinical data have shown that the Ex-PRESS shunt can decrease the frequency of postoperative interventions and anterior chamber bleeding while providing good IOP control that is comparable with that with trabeculectomy.
11,12